Medical Information
Hong Kong
 
This website is intended only for healthcare professionals in the Hong Kong Special Administrative Region (HKSAR). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.
 

Please choose the category that best describes you.

I am a Healthcare Professional in the HKSARYes, I am a healthcare professional
SelectI am a Healthcare Professional in the HKSARYes, I am a healthcare professional
I am NOT a Healthcare ProfessionalNo, go back to the patient portal
SelectI am NOT a Healthcare ProfessionalNo, go back to the patient portal

I am a healthcare professional in another country

CONGRESS MATERIALS

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
Poster
Y. GU, K. HUANG, X. SUN, X. ZHOU, R. SHEN, L. Young, A. CHHABRA, G. DIRUSSO, J. RUPON and I. WINBURN December 10, 2022 ASH 2022 Hemophilia

A Retrospective Cohort Study of Switching Patterns among Hemophilia A and B Patients using Optum Electronic Health Records (EHR) Database in the United States (US)

View Presentation
Poster
John Rasko, George Bashirians, Christos J Petropoulos, Terri Wrin, Yuvika Paliwal, Peter V Henstock, Suryanarayan Somanathan, Michelle Casey, Candida da Fonseca Pereira, Ian Winburn, Amit Chhabra December 10, 2022 ASH 2022 Hemophilia

Global Seroprevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Serotypes of Relevance to Gene Therapy

View Presentation
Poster
Adam Giermasz, Nathan Visweshwar, Thomas J Harrington, Andrew D Leavitt, Barbara A Konkle, Jeremy Rupon, Gregory Di Russo, Li-Jung Tseng, Maria de los Angeles Resa, Florence Ganne, Delphine Agathon, Frank Plonski, Didier Rouy, Bettina M Cockroft, Annie Fang, Steven Arkin December 10, 2022 ASH 2022 Hemophilia

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A

View Presentation
Oral Presentation
Kavakli K, Fuiman J, McKay J, Sun P, Rupon J February 9, 2023 EAHAD 2023 Hemophilia

Efficacy and Safety of Fidanacogene Elaparvovec in Adults With Moderately Severe to Severe Hemophilia B: the Phase 3 BENEGENE-2 Gene Therapy Trial

View Presentation
Poster
Rasko J, Chhabra A, Ducore JM, George LA, Giermasz A, High KA, McGuinn CE, O’Brien A, Rupon J, Samelson-Jones BJ, Smith LM, Sullivan SK, Teitel JM, Winburn I February 9, 2023 EAHAD 2023 Hemophilia

Patterns of Joint Bleeds in Patients With Hemophilia B Following Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy

View Presentation
Poster
Rasko J, Bashirians G, Petropoulos CJ, Wrin T, Somanathan S, Paliwal Y, Henstock PV, da Fonseca Pereira C, Winburn I, Chhabra A February 9, 2023 EAHAD 2023 Hemophilia

Seroprevalence of Neutralizing Antibodies Against Adeno-Associated Virus Serotypes of Relevance to Gene Therapy in Europeans

View Presentation
Poster
Cuker A, Alzahrani H, Astermark J, Frenzel L, Katsarou O, Kavakli K, Klamroth R, Matino D, Shapiro A, Wang J, Fuiman J, McKay J, Sun P, Patel P, Christopher S, Rupon J August 17, 2023 NHF 2023 Hemophilia

Efficacy and Safety of Fidanacogene Elaparvovec in Adults With Moderately Severe or Severe Hemophilia B: Results From the Phase 3 BENEGENE-2 Gene Therapy Trial

View Presentation
Poster
Giermasz A, Visweshwar N, Harrington T, Leavitt A, Konkle B, Rupon J, Di Russo G, Tseng L, de los Angeles Resa M, Ganne F, Agathon D, Plonski F, Rouy D, Cockroft B, Fang A, Patel P, Christopher S, Arkin S August 17, 2023 NHF 2023 Hemophilia

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A

View Presentation